Akebia Therapeutics Inc. (NASDAQ: AKBA)’s stock price has increased by 3.53 compared to its previous closing price of 1.36. However, the company has seen a 0.57% increase in its stock price over the last five trading sessions. MarketBeat reported 2024-04-03 that Akebia Therapeutics Inc. NASDAQ: AKBA is a biopharmaceutical company specializing in developing treatments for chronic kidney diseases (CKD) and anemia management for patients with CKD. The medical sector company addresses unmet needs in the segment.
Is It Worth Investing in Akebia Therapeutics Inc. (NASDAQ: AKBA) Right Now?
Moreover, the 36-month beta value for AKBA is 0.92. Analysts have varying opinions on the stock, with 6 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for AKBA is 186.68M and currently, short sellers hold a 7.18% of that float. On April 23, 2024, AKBA’s average trading volume was 4.80M shares.
AKBA’s Market Performance
AKBA’s stock has seen a 0.57% increase for the week, with a -35.12% drop in the past month and a 0.57% gain in the past quarter. The volatility ratio for the week is 6.02%, and the volatility levels for the past 30 days are at 10.46% for Akebia Therapeutics Inc. The simple moving average for the past 20 days is -11.70% for AKBA’s stock, with a 6.80% simple moving average for the past 200 days.
Analysts’ Opinion of AKBA
Many brokerage firms have already submitted their reports for AKBA stocks, with BTIG Research repeating the rating for AKBA by listing it as a “Buy.” The predicted price for AKBA in the upcoming period, according to BTIG Research is $4 based on the research report published on November 29, 2023 of the previous year 2023.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see AKBA reach a price target of $3.75. The rating they have provided for AKBA stocks is “Buy” according to the report published on August 28th, 2023.
Piper Sandler gave a rating of “Overweight” to AKBA, setting the target price at $4 in the report published on May 31st of the previous year.
AKBA Trading at -11.50% from the 50-Day Moving Average
After a stumble in the market that brought AKBA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -43.23% of loss for the given period.
Volatility was left at 10.46%, however, over the last 30 days, the volatility rate increased by 6.02%, as shares sank -36.43% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -14.33% lower at present.
During the last 5 trading sessions, AKBA rose by +0.36%, which changed the moving average for the period of 200-days by +37.75% in comparison to the 20-day moving average, which settled at $1.5543. In addition, Akebia Therapeutics Inc. saw 13.55% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AKBA starting from Butler John P., who sale 46,570 shares at the price of $1.58 back on Feb 29 ’24. After this action, Butler John P. now owns 2,044,580 shares of Akebia Therapeutics Inc., valued at $73,581 using the latest closing price.
Dahan Michel, the SVP, Chief Operating Officer of Akebia Therapeutics Inc., sale 8,661 shares at $1.58 during a trade that took place back on Feb 29 ’24, which means that Dahan Michel is holding 706,932 shares at $13,684 based on the most recent closing price.
Stock Fundamentals for AKBA
Current profitability levels for the company are sitting at:
- -0.23 for the present operating margin
- 0.62 for the gross margin
The net margin for Akebia Therapeutics Inc. stands at -0.21. The total capital return value is set at -0.32. Equity return is now at value -554.87, with -17.15 for asset returns.
Based on Akebia Therapeutics Inc. (AKBA), the company’s capital structure generated 1.47 points at debt to capital in total, while cash flow to debt ratio is standing at -0.25. The debt to equity ratio resting at -3.11. The interest coverage ratio of the stock is -16.56.
Currently, EBITDA for the company is -4.23 million with net debt to EBITDA at -2.35. When we switch over and look at the enterprise to sales, we see a ratio of 1.82. The receivables turnover for the company is 4.96for trailing twelve months and the total asset turnover is 0.81. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.18.
Conclusion
To wrap up, the performance of Akebia Therapeutics Inc. (AKBA) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
